On October 18th, the core team of Minkai Biomedical visited the Champalimaud Foundation in Lisbon, Portugal, which marked the full launch of the strategic collaboration between the two
parties. During the exchange, both sides clarified specific details such as clinical trial indications and R&D pipelines, signifying Minkai Biomedical's deep involvement in the research, development, and clinical advancement of cancer vaccines. Simultaneously, the "Innovative Cancer Vaccine and Immunotherapy Research Center" was officially inaugurated at the Champalimaud Foundation, providing tangible support for in-person collaboration and the implementation of clinical studies. The core research and clinical teams from both sides have been fully established and are now fully engaged, initiating a new chapter of practical cooperation in China-Europe cancer immunotherapy.

Cancer is one of the world's most significant health challenges. According to the World Health Organization (WHO), in 2022 alone, there were approximately 20 million new cancer cases and
9.7 million cancer-related deaths worldwide, with new cases projected to exceed 35 million by 2050. As the global cancer burden continues to rise rapidly, traditional treatment approaches like surgery, radiotherapy, and chemotherapy have achieved certain success in prolonging patient survival. However, many cancers, especially refractory ones like pancreatic cancer, still have very low survival rates, and issues like recurrence and drug resistance often occur in advanced stages after prolonged traditional treatment. This has prompted scientists to explore more precise and effective treatment approaches.

The field of cancer treatment is undergoing an unprecedented transformation. From traditional therapies to targeted therapies, and now to immunotherapy, medical science is advancing
rapidly toward "precision" and "personalization." In this process, specific targets are a crucial factor.